Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following:

  * Aplastic anemia not responsive to immunosuppressive therapy
  * Metastatic renal cell carcinoma
  * Hematologic malignancy, including any of the following:

    * Acute myeloid leukemia (AML)\* not curable with chemotherapy and meeting any of the following criteria:

      * AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q, complex, Philadelphia chromosome-positive \[Ph+\])
      * AML evolved from prior myelodysplasia
      * AML secondary to prior chemotherapy
      * Failed to achieve remission
      * In second or subsequent remission NOTE: \*Marrow blasts \< 10%- can be achieved by chemotherapy
    * Myelodysplasia\* with any of the following high-risk features:

      * Adverse cytogenetics (-7, 7q, -5, -5q, complex)
      * Excess blasts
      * Prior conversion to AML
      * Severe cytopenias with absolute neutrophil count \< 500/mm\^3 or platelet count \< 20,000/mm\^3 NOTE: \*Marrow blasts \< 10%- can be achieved by chemotherapy
    * Acute lymphoblastic leukemia (ALL)\* not curable with chemotherapy and meeting any of the following criteria:

      * High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7)
      * More than 1 induction course required to achieve remission
      * Failed to enter remission
      * In second or subsequent remission NOTE: \*Marrow blasts \< 10 %
    * Chronic lymphocytic leukemia (CLL) with high-risk features, including any of the following:

      * Refractory to initial or subsequent therapy
      * Progression after initial response to therapy
      * Prolymphocytic morphology
    * Follicular lymphoma with any of the following high-risk features:

      * Refractory to initial or subsequent therapy
      * Progression after response to initial therapy
      * Has ≥ 3 International Prognostic Index (IPI) risk factors
    * Multiple myeloma

      * Stage II-III disease confirmed at diagnosis or after initial progression
    * Other lymphoma that has failed to respond to primary therapy, progressed, or recurred after prior therapy, including any of the following:

      * Diffuse large cell lymphoma
      * Mantle cell lymphoma
      * Hodgkin's lymphoma
    * Myeloproliferative disease with evidence of disease acceleration, including any of the following:

      * Myelofibrosis
      * Polycythemia vera
      * Essential thrombocythemia
    * Chronic myeloid leukemia (CML) that failed to be controlled by imatinib mesylate
* Disease must be stable or responding to therapy
* No rapid progression of malignant disease

  * Expected time to disease progression \> 12 weeks
* Not eligible for autologous stem cell transplantation
* Matched unrelated donor available

  * 9/10 HLA matched, including HLA-A, -B, -C, -DR, and -DQ

PATIENT CHARACTERISTICS:

* Creatinine \< 2.0 mg/dL
* Creatinine clearance \> 40 mL/min
* Bilirubin \< 3 mg/dL

  * Elevated total bilirubin due to Gilbert's disease allowed if direct bilirubin is normal
* AST \< 4 times upper limit of normal
* Hepatitis C or B allowed provided bilirubin and AST are normal
* Cardiac ejection fraction \> 30%
* DLCO \> 40% of predicted
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No uncontrolled active infection requiring ongoing antibiotic treatment
* No poor performance status
* No poor organ function

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior stem cell or bone marrow transplantation allowed